Healthcare Providers and Services
Company Overview of Joslin Diabetes Center, Inc.
Joslin Diabetes Center, Inc. operates a diabetes treatment, research, and education institution. It offers research programs for preventing and curing type 1 and type 2 diabetes and their long-term complications. The company also provides diabetes care services for adult and pediatric patients. In addition, it develops and markets programs, products, and services for the availability of the company’s knowledge and expertise to people with diabetes and the clinicians caring for them. Joslin Diabetes Center, Inc. was founded in 1898 and is headquartered in Boston, Massachusetts.
One Joslin Place
Boston, MA 02215
Founded in 1898
Key Executives for Joslin Diabetes Center, Inc.
Chief Executive Officer, President and Trustee
Chief Scientific Officer, Senior Vice President and Trustee
Senior Vice President of Medical Affairs
Compensation as of Fiscal Year 2014.
Joslin Diabetes Center, Inc. Key Developments
Joslin Diabetes Center and Daegu-Gyeongbuk Free Economic Zone Sign MoU to Explore Opportunities to Collaborate
Mar 12 15
Joslin Diabetes Center and Daegu-Gyeongbuk Free Economic Zone have signed a memorandum of understanding formalizing their mutual strong commitment to navigate avenues for potential partnership. The MoU signing is an important step towards establishing a partnership that will allow Joslin to potentially establish a physical presence in the Daegu-Gyeongbuk area, bringing Joslin’s mission of preventing, treating and curing diabetes to the region. There were an estimated 2.7 million cases of diabetes in the Republic of Korea in 2014.
MedImmune and Joslin Diabetes Center Announce New Research Collaboration Focused on Advancing Metabolic Disease Research
Mar 10 15
MedImmune and Joslin Diabetes Center announced a three-year research collaboration to develop new medicines for the treatment of diabetes, obesity, and related metabolic disorders. MedImmune and Joslin researchers will work collaboratively on research projects to identify new drug candidates. Three initial projects have been identified, focusing on several key areas including protecting and regenerating the insulin producing beta cells, increasing the caloric utilization of fat depots ('beiging' white fat or expanding brown fat), and replicating the beneficial effects of bariatric surgery pharmacologically. The collaboration is structured with the potential for more projects to be added as new compelling science is identified. Under the terms of the agreement, MedImmune will provide research funding to Joslin and bring drug development expertise and capabilities to complement Joslin's early metabolic disease research competencies and clinical care infrastructure. MedImmune has the option to license development and commercial rights to projects emerging from the collaboration.
EKF Diagnostics Enters into Multi-Year, Collaborative Relationship with Joslin Diabetes Center in Support of the Ongoing Clinical and Commercial Translation
Nov 18 14
EKF Diagnostics has entered a multi-year, collaborative relationship with Joslin Diabetes Center in support of the ongoing clinical and commercial translation of TNFR1 & 2 biomarkers. These novel biomarkers can help identify patients with Type 1 and Type 2 diabetes that are at an increased risk of developing end stage renal disease (ESRD), up to ten years in advance. The new agreement between Joslin, an affiliate of Harvard Medical School, and EKF is part of Joslin's Corporate Liaison Program (CLP). This program seeks to accelerate development, validation and market introduction of unique products and solutions that advance treatments and care for diabetes and its complications. As globally recognized leaders in the field of diabetes research, Joslin has created the CLP in order to foster industry partnerships within the pharmaceutical, biotechnology, food and device industries. The role of the CLP is to help engage corporate partners, such as EKF, with Joslin's capabilities in advisory services, clinical expertise, and research infrastructure. This enables Joslin to work closely with an industry partner to customize its offerings towards a defined product program or a range of corporate priorities within diabetes management.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|